biostudies-literatureUnknown8Schutte MColorectal carcinoma represents a heterogeneous entity, with only a fraction of the tumours responding to available therapies, requiring a better molecular understanding of the disease in precision oncology. To address this challenge, the OncoTrack consortium recruited 106 CRC patients (stages I-IV) and developed a pre-clinical platform generating a compendium of drug sensitivity data totalling >4,000 assays testing 16 clinical drugs on patient-derived in vivo and in vitro models. This large biobank of 106 tumours, 35 organoids and 59 xenografts, with extensive omics data comparing donor tumours and derived models provides a resource for advancing our understanding of CRC. Models recapitulate many of the genetic and transcriptomic features of the donors, but defined less complex molecular Nature communications14262https://www.ebi.ac.uk/biostudies/studies/S-EPMC5309787biostudies-literatureMolecular dissection of colorectal cancer in pre-clinical models identifies biomarkers predicting sensitivity to EGFR inhibitors.PMC5309787Nilsson MBorodina THerwig RBecker MAmstislavskiy VAbdavi-Azar NButcher LMWierling CReinhard CSchweiger CVelasco JAGarin-Chesa PLehrach HYildiriman RWelte YWienke DLange MSchumacher DSilvestrov MKessler TGolob-Schwarzl NUranitsch SKeilholz URegan JLBeck SSchafer RLandegren ULange BLax SYaspo MLWorth CLLiebs SBarrett JESultan MHaybaeck JKehler IRegenbrecht CRKeil MWarnatz HJBoehnke KHoffmann JSchutte MHenderson DRisch TJandrasits CFusi AfalseMolecular dissection of colorectal cancer in pre-clinical models identifies biomarkers predicting sensitivity to EGFR inhibitors.Colorectal carcinoma represents a heterogeneous entity, with only a fraction of the tumours responding to available therapies, requiring a better molecular understanding of the disease in precision oncology. To address this challenge, the OncoTrack consortium recruited 106 CRC patients (stages I-IV) and developed a pre-clinical platform generating a compendium of drug sensitivity data totalling >4,000 assays testing 16 clinical drugs on patient-derived in vivo and in vitro models. This large biobank of 106 tumours, 35 organoids and 59 xenografts, with extensive omics data comparing donor tumours and derived models provides a resource for advancing our understanding of CRC. Models recapitulate many of the genetic and transcriptomic features of the donors, but defined less complex molecular 2017-01-01T00:00:00Z2017 Feb2026-04-28T23:23:53.29Z2019-03-27T02:36:33ZS-EPMC53097872818612610.1038/ncomms14262